Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas
US4935495A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 21, 1984 |
| Grant date | Jun 19, 1990 |
| Priority date | — |
| Expiry date | Dec 21, 2004 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is concerned with novel monoclonal antibodies which define a gylcolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagonostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.